When we used a virus to drive a large over-expression of the microRNA
, there was no effect on the behaviour of the limited-access animals.
The first microRNA
diagnostic test applying Rosetta Genomics' technology has been approved for clinical use by the State of New York, and the company expects it will be launched by licensed clinical laboratories in the United States in 2008.
Much of our work surrounds discovering microRNA
biomarkers, and given how much is known about the connection between microRNA
and cancer, we believe that we are in a unique position to advance the fields of cancer diagnosis, prognosis and therapeutics.
Only a few years ago, biologists stumbled upon the fact that cells use RNA snippets called microRNAs
as tools to control the activity of genes.
SM] plans to support Regulus' microRNA
therapeutics programs and its academic research partners by expanding the scope of the division's work.
The study further shows that by treating the cells with "anti-sense" RNA antagonists (inhibitors) to specific microRNA
or by employing mimics of a particular microRNA
, one can reverse the pattern of expression of a given target gene regulated by that microRNA
The study results, published in Brain Pathology, describe the development and validation of microRNA
expression profiles for characterization of brain malignancies.
Protect uses of microRNA
sequences and targets for development of diagnostics and therapeutics - Rosetta Genomics has filed patent applications covering the use of microRNAs
as diagnostic biomarkers and therapeutic targets.
Regulus believes that it has a leading intellectual property position and substantial know-how relating to the development and commercialization of microRNA
therapeutics in a wide range of therapeutic areas.
a US-based microRNA
therapeutics company, have collaborated in their efforts to discover and develop microRNA
biomarkers for multiple sclerosis.
Select Biosciences has performed worldwide market tracking wherein analyzed end-user research trends in the microRNA
as well as Exosome markets—these areas are evolving in parallel given the opportunity in the Circulating Biomarkers space and the utility of microRNAs
and mRNAs to be harvested from exosomes and assayed as signatures for disease.
Director, Oncogenomics Core Facility, Sylvester Cancer Center, University of Miami School of Medicine, USA, has presented data from a larger validation study of Exiqon's miRCURY LNA(TM) Universal RT microRNA
PCR product line.